• AstraZeneca rare-disease unit Alexion outlined new neurology data to be presented at American Academy of Neurology annual meeting in Chicago on April 18-22, 2026.
• PREVAIL Phase 3 results due April 20 will show investigational once-weekly, self-administered C5 inhibitor gefurulimab improved symptoms in adults with AChR antibody-positive generalized myasthenia gravis versus placebo.
• Alexion noted earlier PREVAIL findings were already presented at 2025 MGFA scientific session during AANEM annual meeting.
• KOMET Phase 3 qualitative sub-study scheduled for April 20 will indicate Koselugo reduced pain and other symptom burden in adults with neurofibromatosis type 1 plexiform neurofibromas.
• Additional AAN presentations will include real-world evidence on Ultomiris in neuromyelitis optica spectrum disorder, supporting use of complement inhibition in clinical practice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202604100207BITN____UKPR__SV_20260409-BIT-6755-0) on April 10, 2026, and is solely responsible for the information contained therein.